Fiche société
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Traitements, essais et publications liés.
Traitements4programmes
Essais2liés
Publications0liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| IMPT-514 CART Cell InjectionThis is an exploratory trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of IMPT-514, an autologous, anti-CD19/CD20 CAR T therapy, administered as an intravenous (IV) infusion, in participants with B cell driven autoimmune diseases, including active, refractory Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), and Idiopathic Inflammatory Myopathy (IIM). | SEP | Phase 1 | Immunomodulation | China | À vérifier |
| SNC116This study aims to evaluate the safety and tolerability of SNC116 in treating patients with systemic lupus erythematosus. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| SNC116This study aims to evaluate the safety and tolerability of SNC116 in treating patients with systemic lupus erythematosus. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| IMPT-514 CART Cell InjectionThis is an exploratory trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of IMPT-514, an autologous, anti-CD19/CD20 CAR T therapy, administered as an intravenous (IV) infusion, in participants with B cell driven autoimmune diseases, including active, refractory Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), and Idiopathic Inflammatory Myopathy (IIM). | SEP | Phase 1 | Immunomodulation | China | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| IMPT-514 CART Cell Injection | SEP | Phase 1 | NCT06462144 | IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy | TERMINATED |
| SNC116 | Lupus | Phase 1 | NCT07748156 | SNC116 Therapy for Refractory Systemic Lupus Erythematosus | NOT_YET_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||